NCT04019262View on ClinicalTrials.gov

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
Glioblastoma
Interventions
RADIATION

Radiation Therapy

Radiation

DRUG

Temozolomide Oral Product

Oral Temozolomide (150mg/m\^2 or 75 mg/m\^2)

Trial Locations (1)

15232

University of Pittsburgh Medical Center, Radiation Oncology, Pittsburgh

All Listed Sponsors
lead

John Flickinger

OTHER